Format

Send to

Choose Destination
J Infect Dis. 2016 Oct 15;214(suppl 3):S333-S341. Epub 2016 Aug 11.

Preliminary Evaluation of the Effect of Investigational Ebola Virus Disease Treatments on Viral Genome Sequences.

Author information

1
Viral Special Pathogens Branch.
2
Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
3
Institute of Evolutionary Biology, University of Edinburgh, United Kingdom.
4
Biotechnology Core Facility Branch.

Abstract

BACKGROUND:

Several patients with Ebola virus disease (EVD) managed in the United States have received ZMapp monoclonal antibodies, TKM-Ebola small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics.

METHODS:

To investigate whether treatment selected for Ebola virus (EBOV) mutations conferring resistance, viral sequencing was performed on RNA extracted from clinical blood specimens from patients with EVD following treatment, and putative viral targets were analyzed.

RESULTS:

We observed no major or minor EBOV mutations within regions targeted by therapeutics.

CONCLUSIONS:

This small subset of patients and clinical specimens suggests that evolution of resistance is not a direct consequence of antiviral treatment. As EVD antiviral treatments are introduced into wider use, it is essential that continuous viral full-genome surveillance is performed, to monitor for the emergence of escape mutations.

KEYWORDS:

Ebola virus; antiviral agents; directed molecular evolution; high-throughput nucleotide sequencing; molecular epidemiology

PMID:
27521366
DOI:
10.1093/infdis/jiw177
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center